Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents

European cancer mortality predictions for the year 2014

(2014) M. Malvezzi et al.   ANNALS OF ONCOLOGY

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

(2014) Emmanuel S. Antonarakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor clone dynamics in lethal prostate cancer

(2014) S. Carreira et al.   Science Translational Medicine

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)

(2013) Y. Loriot et al.   ANNALS OF ONCOLOGY

Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker

(2013) Yi Liu et al.   BMC CANCER

Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade

(2013) Vivek K. Arora et al.   CELL

Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone

(2013) D. Bianchini et al.   EUROPEAN JOURNAL OF CANCER

Development of a method to isolate circulating tumor cells using mesenchymal-based capture

(2013) Rhonda L. Bitting et al.   METHODS

Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer

(2012) S. T. Ligthart et al.   ANNALS OF ONCOLOGY

Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100

(2012) J. Richards et al.   CANCER RESEARCH

FoxA1 Specifies Unique Androgen and Glucocorticoid Receptor Binding Events in Prostate Cancer Cells

(2012) B. Sahu et al.   CANCER RESEARCH

Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non-Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib

(2012) E. A. Punnoose et al.   CLINICAL CANCER RESEARCH

Challenges in Recognizing Treatment-Related Neuroendocrine Prostate Cancer

(2012) Himisha Beltran et al.   JOURNAL OF CLINICAL ONCOLOGY

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

(2012) Howard I. Scher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate Cancer

(2012) David T. Miyamoto et al.   Cancer Discovery

Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer

(2011) M. S. Darshan et al.   CANCER RESEARCH

Abiraterone and Increased Survival in Metastatic Prostate Cancer

(2011) Johann S. de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

Unbiased and Automated Identification of a Circulating Tumour Cell Definition That Associates with Overall Survival

(2011) Sjoerd T. Ligthart et al.   PLoS One

Monitoring Drug-Induced  H2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells

(2010) L. H. Wang et al.   CLINICAL CANCER RESEARCH

Utilizing circulating tumor cells: challenges and pitfalls

(2010) Gerhardt Attard et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?

(2009) Gerhardt Attard et al.   CANCER CELL

Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer

(2009) G. Attard et al.   CANCER RESEARCH

Characterization of circulating tumor cells by fluorescence in situ hybridization

(2009) Joost F. Swennenhuis et al.   CYTOMETRY PART A

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

(2008) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY